CHAMPIONS ONCOLOGY INC (CSBR) Stock Fundamental Analysis
USA - NASDAQ:CSBR - US15870P3073 - Common Stock
6.487 USD
-0.07 (-1.11%)
We assign a fundamental rating of 5 out of 10 to CSBR. CSBR was compared to 56 industry peers in the Life Sciences Tools & Services industry. CSBR has a medium profitability rating, but doesn't score so well on its financial health evaluation. CSBR has a correct valuation and a medium growth rate.
1. Profitability
1.1 Basic Checks
In the past year CSBR was profitable.
CSBR had a positive operating cash flow in the past year.
In multiple years CSBR reported negative net income over the last 5 years.
The reported operating cash flow has been mixed in the past 5 years: CSBR reported negative operating cash flow in multiple years.
1.2 Ratios
CSBR's Return On Assets of 9.66% is amongst the best of the industry. CSBR outperforms 87.50% of its industry peers.
With an excellent Return On Equity value of 84.15%, CSBR belongs to the best of the industry, outperforming 98.21% of the companies in the same industry.
CSBR has a better Return On Invested Capital (30.30%) than 96.43% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 9.66% | ||
| ROE | 84.15% | ||
| ROIC | 30.3% |
ROA(3y)-9.62%
ROA(5y)-5.2%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin of CSBR (5.19%) is better than 67.86% of its industry peers.
In the last couple of years the Profit Margin of CSBR has grown nicely.
Looking at the Operating Margin, with a value of 5.29%, CSBR is in the better half of the industry, outperforming 60.71% of the companies in the same industry.
CSBR's Operating Margin has improved in the last couple of years.
CSBR has a Gross Margin (48.47%) which is comparable to the rest of the industry.
CSBR's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 5.29% | ||
| PM (TTM) | 5.19% | ||
| GM | 48.47% |
OM growth 3Y89.93%
OM growth 5YN/A
PM growth 3Y94.62%
PM growth 5YN/A
GM growth 3Y-1.13%
GM growth 5Y1.11%
2. Health
2.1 Basic Checks
CSBR has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
The number of shares outstanding for CSBR has been increased compared to 1 year ago.
Compared to 5 years ago, CSBR has more shares outstanding
Compared to 1 year ago, CSBR has a worse debt to assets ratio.
2.2 Solvency
Based on the Altman-Z score of 0.45, we must say that CSBR is in the distress zone and has some risk of bankruptcy.
CSBR has a worse Altman-Z score (0.45) than 71.43% of its industry peers.
CSBR has a debt to FCF ratio of 0.03. This is a very positive value and a sign of high solvency as it would only need 0.03 years to pay back of all of its debts.
CSBR has a Debt to FCF ratio of 0.03. This is amongst the best in the industry. CSBR outperforms 92.86% of its industry peers.
CSBR has a Debt/Equity ratio of 0.02. This is a healthy value indicating a solid balance between debt and equity.
The Debt to Equity ratio of CSBR (0.02) is better than 66.07% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.02 | ||
| Debt/FCF | 0.03 | ||
| Altman-Z | 0.45 |
ROIC/WACC2.91
WACC10.42%
2.3 Liquidity
A Current Ratio of 0.93 indicates that CSBR may have some problems paying its short term obligations.
With a Current ratio value of 0.93, CSBR is not doing good in the industry: 91.07% of the companies in the same industry are doing better.
A Quick Ratio of 0.93 indicates that CSBR may have some problems paying its short term obligations.
CSBR has a worse Quick ratio (0.93) than 83.93% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.93 | ||
| Quick Ratio | 0.93 |
3. Growth
3.1 Past
CSBR shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 289.47%, which is quite impressive.
Measured over the past years, CSBR shows a very strong growth in Earnings Per Share. The EPS has been growing by 146.62% on average per year.
The Revenue has grown by 10.11% in the past year. This is quite good.
CSBR shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 12.13% yearly.
EPS 1Y (TTM)289.47%
EPS 3Y146.62%
EPS 5YN/A
EPS Q2Q%-81.82%
Revenue 1Y (TTM)10.11%
Revenue growth 3Y5.06%
Revenue growth 5Y12.13%
Sales Q2Q%-0.47%
3.2 Future
CSBR is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -41.69% yearly.
CSBR is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 18.26% yearly.
EPS Next Y-50.13%
EPS Next 2Y-41.69%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year5.84%
Revenue Next 2Y8.88%
Revenue Next 3Y18.44%
Revenue Next 5Y18.26%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 18.02 indicates a rather expensive valuation of CSBR.
Based on the Price/Earnings ratio, CSBR is valued cheaper than 87.50% of the companies in the same industry.
The average S&P500 Price/Earnings ratio is at 27.40. CSBR is valued slightly cheaper when compared to this.
Based on the Price/Forward Earnings ratio of 42.40, the valuation of CSBR can be described as expensive.
CSBR's Price/Forward Earnings is on the same level as the industry average.
CSBR is valuated expensively when we compare the Price/Forward Earnings ratio to 22.94, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 18.02 | ||
| Fwd PE | 42.4 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of CSBR indicates a rather cheap valuation: CSBR is cheaper than 80.36% of the companies listed in the same industry.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of CSBR indicates a rather cheap valuation: CSBR is cheaper than 96.43% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 12.42 | ||
| EV/EBITDA | 17.62 |
4.3 Compensation for Growth
The decent profitability rating of CSBR may justify a higher PE ratio.
CSBR's earnings are expected to decrease with -41.69% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-41.69%
EPS Next 3YN/A
5. Dividend
5.1 Amount
CSBR does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NASDAQ:CSBR (10/17/2025, 8:04:22 PM)
6.487
-0.07 (-1.11%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners48.17%
Inst Owner Change0%
Ins Owners26.06%
Ins Owner Change0%
Market Cap89.46M
Analysts82.86
Price Target12.24 (88.69%)
Short Float %0.9%
Short Ratio2.44
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)180.88%
Min EPS beat(2)65.69%
Max EPS beat(2)296.08%
EPS beat(4)4
Avg EPS beat(4)1095.34%
Min EPS beat(4)65.69%
Max EPS beat(4)3629.41%
EPS beat(8)7
Avg EPS beat(8)599.88%
EPS beat(12)8
Avg EPS beat(12)365.32%
EPS beat(16)10
Avg EPS beat(16)266.15%
Revenue beat(2)2
Avg Revenue beat(2)1.19%
Min Revenue beat(2)0.83%
Max Revenue beat(2)1.54%
Revenue beat(4)4
Avg Revenue beat(4)8.21%
Min Revenue beat(4)0.83%
Max Revenue beat(4)29.17%
Revenue beat(8)6
Avg Revenue beat(8)2.62%
Revenue beat(12)7
Avg Revenue beat(12)0.98%
Revenue beat(16)10
Avg Revenue beat(16)1.06%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-87.5%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-9.56%
Revenue NY rev (1m)-1.82%
Revenue NY rev (3m)-1.82%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 18.02 | ||
| Fwd PE | 42.4 | ||
| P/S | 1.57 | ||
| P/FCF | 12.42 | ||
| P/OCF | 11.72 | ||
| P/B | 25.5 | ||
| P/tB | 28.19 | ||
| EV/EBITDA | 17.62 |
EPS(TTM)0.36
EY5.55%
EPS(NY)0.15
Fwd EY2.36%
FCF(TTM)0.52
FCFY8.05%
OCF(TTM)0.55
OCFY8.53%
SpS4.12
BVpS0.25
TBVpS0.23
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 9.66% | ||
| ROE | 84.15% | ||
| ROCE | 38.35% | ||
| ROIC | 30.3% | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | 5.29% | ||
| PM (TTM) | 5.19% | ||
| GM | 48.47% | ||
| FCFM | 12.66% |
ROA(3y)-9.62%
ROA(5y)-5.2%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3Y89.93%
OM growth 5YN/A
PM growth 3Y94.62%
PM growth 5YN/A
GM growth 3Y-1.13%
GM growth 5Y1.11%
F-Score7
Asset Turnover1.86
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.02 | ||
| Debt/FCF | 0.03 | ||
| Debt/EBITDA | 0.01 | ||
| Cap/Depr | 28.08% | ||
| Cap/Sales | 0.76% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 167.47% | ||
| Profit Quality | 243.9% | ||
| Current Ratio | 0.93 | ||
| Quick Ratio | 0.93 | ||
| Altman-Z | 0.45 |
F-Score7
WACC10.42%
ROIC/WACC2.91
Cap/Depr(3y)65.35%
Cap/Depr(5y)124.01%
Cap/Sales(3y)2.56%
Cap/Sales(5y)4.1%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)289.47%
EPS 3Y146.62%
EPS 5YN/A
EPS Q2Q%-81.82%
EPS Next Y-50.13%
EPS Next 2Y-41.69%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)10.11%
Revenue growth 3Y5.06%
Revenue growth 5Y12.13%
Sales Q2Q%-0.47%
Revenue Next Year5.84%
Revenue Next 2Y8.88%
Revenue Next 3Y18.44%
Revenue Next 5Y18.26%
EBIT growth 1Y199.05%
EBIT growth 3Y99.53%
EBIT growth 5YN/A
EBIT Next Year-7.31%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y375.86%
FCF growth 3Y19.31%
FCF growth 5Y58.93%
OCF growth 1Y4141.67%
OCF growth 3Y4.35%
OCF growth 5Y20.48%